Formulation strategies for absorption windows.

Absorption windows in the proximal gut can limit the bioavailability of orally administered compounds and can be a major obstacle to the development of controlled release formulations for important drugs. Methods to increase the residence of drug formulations at or above the absorption window are discussed in this review. Two main approaches are presently being explored: (i) bioadhesive microspheres that have a slow intestinal transit; and (ii) the gastroretentive dosage system, which is based on multiparticulates or large single unit systems. A good understanding of gastrointestinal transit in humans and the effect of factors such as food can be helpful in the design of rational systems that will have clinical benefit.

[1]  G. Houin,et al.  Localisation of drug permeability along the rat small intestine, using markers of the paracellular, transcellular and some transporter routes. , 2004, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[2]  Clive G. Wilson,et al.  Gastrointestinal transit of a controlled-release pellet formulation of tiaprofenic acid and the effect of food , 1987 .

[3]  Brahma N. Singh.  Effects of Food on Clinical Pharmacokinetics , 1999, Clinical pharmacokinetics.

[4]  I. Wilding,et al.  The effect of mannitol on the oral bioavailability of cimetidine. , 1995, Journal of pharmaceutical sciences.

[5]  J. Mathias,et al.  Escherichia coli heat-stable toxin: its effect on motility of the small intestine. , 1982, The American journal of physiology.

[6]  A. Hoffman,et al.  Novel Gastroretentive Dosage Forms: Evaluation of Gastroretentivity and Its Effect on Levodopa Absorption in Humans , 2003, Pharmaceutical Research.

[7]  David V. Prior,et al.  Remote controlled capsules in human drug absorption (HDA) studies. , 2003, Critical reviews in therapeutic drug carrier systems.

[8]  K. Matsuda,et al.  Improvement in site‐specific intestinal absorption of furosemide by Eudragit L100‐55 , 2001, The Journal of pharmacy and pharmacology.

[9]  Sara Eyal,et al.  Novel levodopa gastroretentive dosage form: in-vivo evaluation in dogs. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[10]  S. Torrado,et al.  Chitosan-poly(acrylic) acid polyionic complex: in vivo study to demonstrate prolonged gastric retention. , 2004, Biomaterials.

[11]  M. Donnenberg,et al.  Enteropathogenic Escherichia coli (EPEC) adhesion to intestinal epithelial cells: role of bundle-forming pili (BFP), EspA filaments and intimin. , 2004, Microbiology.

[12]  J. Azuma,et al.  Evaluation of Oral Mucoadhesive Microspheres in Man on the Basis of the Pharmacokinetics of Furosemide and Riboflavin, Compounds with Limited Gastrointestinal Absorption Sites , 1998, The Journal of pharmacy and pharmacology.

[13]  O. Corrigan.  The biopharmaceutic drug classification and drugs administered in extended release (ER) formulations. , 1997, Advances in experimental medicine and biology.

[14]  P. Bass,et al.  GUANOSINE 3′,5′-CYCLIC MONOPHOSPHATE: A TAPEWORM-SECRETED SIGNAL MOLECULE COMMUNICATING WITH THE RAT HOST'S SMALL INTESTINE , 2003, The Journal of parasitology.

[15]  Pharmacoscintigraphic Assessment of the Regional Drug Absorption of the Dual Angiotensin‐Converting Enzyme/Neutral Endopeptidase Inhibitor, M100240, in Healthy Volunteers , 2003, Journal of clinical pharmacology.

[16]  R. Murthy,et al.  Floating dosage systems in drug delivery. , 2002, Critical reviews in therapeutic drug carrier systems.

[17]  J. Schellens,et al.  The Oral Route for the Administration of Cytotoxic Drugs: Strategies to Increase the Efficiency and Consistency of Drug Delivery , 2000, Investigational New Drugs.

[18]  Lawrence X. Yu,et al.  In vitro testing of drug absorption for drug 'developability' assessment: forming an interface between in vitro preclinical data and clinical outcome. , 2004, Current opinion in drug discovery & development.

[19]  V. Cowles,et al.  Gastric retentive dosage forms: a review. , 2003, Critical reviews in therapeutic drug carrier systems.

[20]  S. Davis,et al.  Chitosan microspheres prepared by spray drying. , 1999, International journal of pharmaceutics.

[21]  I. Wilding,et al.  The effect of ileal brake activators on the oral bioavailability of atenolol in man. , 2002, International journal of pharmaceutics.

[22]  H. Onishi,et al.  Prolonged intestinal absorption of cephradine with chitosan-coated ethylcellulose microparticles in rats. , 2002, Biological & pharmaceutical bulletin.

[23]  H. Kanerva,et al.  Gamma scintigraphic evaluation of the fate of microcrystalline chitosan granules in human stomach. , 2004, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[24]  S. Davis,et al.  Alimentary tract andpancreas Transit ofpharmaceutical dosage forms through the , 1986 .

[25]  I. Wilding,et al.  Effect of altered gastric emptying and gastrointestinal motility on metformin absorption. , 2000, British journal of clinical pharmacology.

[26]  A. Hoffman,et al.  Furosemide Pharmacokinetics and Pharmacodynamics following Gastroretentive Dosage Form Administration to Healthy Volunteers , 2003, Journal of clinical pharmacology.

[27]  I. Wilding,et al.  Gastrointestinal transit of a matrix tablet formulation : comparison of canine and human data , 1993 .

[28]  Henry C. Lin,et al.  Slowing of intestinal transit by fat or peptide YY depends on beta-adrenergic pathway. , 2003, American journal of physiology. Gastrointestinal and liver physiology.

[29]  W. Weitschies,et al.  Variability of intestinal expression of P-glycoprotein in healthy volunteers as described by absorption of talinolol from four bioequivalent tablets. , 2003, Journal of pharmaceutical sciences.

[30]  M. Hämäläinen,et al.  Predicting the intestinal absorption potential of hits and leads. , 2004, Drug discovery today. Technologies.

[31]  S. S. Davis,et al.  Gastrointestinal transit of dosage forms in the pig , 2001, The Journal of pharmacy and pharmacology.

[32]  K. Kolter,et al.  Lauroyldextran and crosslinked galactomannan as coating materials for site-specific drug delivery to the colon. , 1999, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[33]  I. Wilding,et al.  The role of γ-scintigraphy in oral drug delivery , 1991 .

[34]  Gerrit Borchard,et al.  In vitro evaluation of intestinal absorption of desmopressin using drug-delivery systems based on superporous hydrogels. , 2004, International journal of pharmaceutics.

[35]  Henry C. Lin,et al.  The ileal brake: A fifteen-year progress report , 1999, Current gastroenterology reports.

[36]  R. Steele,et al.  Intragastric Distribution of Ion‐exchange Resins: a Drug Delivery System for the Topical Treatment of the Gastric Mucosa , 1995, The Journal of pharmacy and pharmacology.

[37]  G. Amidon,et al.  The Site-Specific Transport and Metabolism of Tacrolimus in Rat Small Intestine , 2003, Journal of Pharmacology and Experimental Therapeutics.

[38]  A. Fasano,et al.  The effect of ΔG on the transport and oral absorption of macromolecules , 2004 .

[39]  P. Macheras,et al.  Biopharmaceutics Of Orally Administered Drugs , 1995 .

[40]  P. Watkins,et al.  6′7′‐Dihydroxybergamottin Contributes to the Grapefruit Juice Effect , 2004, Clinical pharmacology and therapeutics.

[41]  G. Ponchel,et al.  Gastrointestinal Transit and Mucoadhesion of Colloidal Suspensions of Lycopersicon Esculentum L. and Lotus Tetragonolobus Lectin-PLA Microsphere Conjugates in Rats , 2001, Pharmaceutical Research.

[42]  Kinam Park,et al.  Gastric retention properties of superporous hydrogel composites. , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[43]  H E Junginger,et al.  Intestinal absorption of human insulin in pigs using delivery systems based on superporous hydrogel polymers. , 2002, International journal of pharmaceutics.

[44]  Y. Machida,et al.  Bioadhesive Characteristics of Chitosan Microspheres to the Mucosa of Rat Small Intestine , 2001, Drug development and industrial pharmacy.